Healthcare Business

Rubius Therapeutics Enters the Market With a Bang

Posted: July 18, 2018 at 1:40 pm

Rubius Therapeutics Inc. (NASDAQ: RUBY) entered the market with a bang in its initial public offering (IPO). The stock entered the market just over $30 per share, well above its ...
Read Full Story »

Pfizer and Eli Lilly Win in Late-Stage Osteoarthitis Study

Posted: July 18, 2018 at 10:00 am

Pfizer Inc. (NYSE: PFE) and Eli Lilly and Co. (NYSE: LLY) shares were largely unaffected after the firms announced results from a joint late-stage trial in patients with osteoarthritis (OA) ...
Read Full Story »

Why Voyager Therapeutics Shares Are Surging

Posted: July 17, 2018 at 12:15 pm

Voyager Therapeutics Inc. (NASDAQ: VYGR) shares saw a handy gain on Tuesday after the company announced that it received some feedback from the U.S. Food and Drug Administration (FDA) from ...
Read Full Story »

Why UnitedHealth Earnings Aren’t Enough

Posted: July 17, 2018 at 10:05 am

UnitedHealth Group Inc. (NYSE: UNH) released its second-quarter financial results before the markets opened on Tuesday. The company said that it had $3.14 in earnings per share (EPS) and $56.1 ...
Read Full Story »

Are Johnson & Johnson Q2 Earnings Good Enough?

Posted: July 17, 2018 at 8:45 am

Johnson & Johnson (NYSE: JNJ) reported its second-quarter financial results before the markets opened on Tuesday. The health care giant said that it had $2.10 in earnings per share (EPS) ...
Read Full Story »

What to Watch For in UnitedHealth Earnings

Posted: July 16, 2018 at 1:35 pm

UnitedHealth Group Inc. (NYSE: UNH) is scheduled to report its second-quarter financial results before the markets open on Tuesday. Thomson Reuters consensus estimates call for $3.04 in earnings per share ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday Morning

Posted: July 16, 2018 at 10:25 am

Johnson & Johnson (NYSE: JNJ) is set to report its second-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters are $2.07 in earnings per ...
Read Full Story »

Why Tonix Pharmaceuticals Is Winning Big on Monday

Posted: July 16, 2018 at 10:05 am

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) saw its shares make a solid gain to start off the week after the company announced an update from the U.S. Food and Drug ...
Read Full Story »

Will Acceleron Pharma Momentum Continue After New FDA Nod?

Posted: July 13, 2018 at 10:30 am

Acceleron Pharma Inc. (NASDAQ: XLRN) shares reached a multiyear high last month after the company and Celgene Corp. (NASDAQ: CELG) announced positive late-stage trial results, but those shares dipped on Friday ...
Read Full Story »

How Zogenix Is Winning Big With Late-Stage Seizure Study

Posted: July 12, 2018 at 11:40 am

Zogenix Inc. (NASDAQ: ZGNX) shares made a solid gain on Thursday after the company announced positive results from its late-stage seizure trial. Essentially, the company reported positive top-line results from ...
Read Full Story »

Where Did Major Pharma Short Sellers Go?

Posted: July 12, 2018 at 8:50 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Back Off Major Biotechs

Posted: July 12, 2018 at 8:21 am

The short interest data are out for the most recent settlement date, June 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Akcea Therapeutics Jumps on European Marketing Approval

Posted: July 11, 2018 at 1:20 pm

Akcea Therapeutics Inc. (NASDAQ: AKCA) shares saw a nice bump on Wednesday after the company announced in conjunction with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) that they had received a marketing ...
Read Full Story »

BioCryst Shareholders Back Out of Idera Merger

Posted: July 11, 2018 at 11:05 am

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) shares crumbled on Wednesday after BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) announced that it terminated their merger agreement. Ultimately the cause of this termination was the ...
Read Full Story »

AbbVie Slumps on Late-Stage Lymphoma Trial

Posted: July 11, 2018 at 10:15 am

AbbVie Inc. (NYSE: ABBV) shares dipped on Wednesday after the company gave a less than impressive update from its late-stage lymphoma trial. Essentially, the company updated its Phase 3 study ...
Read Full Story »